OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
-21.81%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.29%
AUM
$222M
AUM Growth
+$222M
(-31%)
Cap. Flow
-$21.7M
Cap. Flow
% of AUM
-9.76%
Top 10 Holdings %
Top 10 Hldgs %
58.76%
Holding
56
New
11
Increased
13
Reduced
17
Closed
9
Top Buys
| 1 |
TELA Bio
TELA
|
$8.18M |
| 2 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
$6.7M |
| 3 |
CUTR
Cutera, Inc.
CUTR
|
$5.54M |
| 4 |
UroGen Pharma
URGN
|
$1.96M |
| 5 |
TCON
TRACON Pharmaceuticals, Inc. Common Stock
TCON
|
$1.94M |
Top Sells
| 1 |
CMRX
Chimerix, Inc.
CMRX
|
$9.3M |
| 2 |
BCYC
Bicycle Therapeutics
BCYC
|
$7.68M |
| 3 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$6.78M |
| 4 |
Protagonist Therapeutics
PTGX
|
$5.96M |
| 5 |
Cytokinetics
CYTK
|
$4.09M |
Sector Composition
| 1 | Healthcare | 99.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Harrow
HROW
$1.44B
| $24.3M | 10.94% | 3,332,732 +41,389 | +1% | +$301K |
|
2
Ocular Therapeutix
OCUL
$2.12B
| $24M | 10.83% | 5,974,800 | – | – |
|
3
Codexis
CDXS
$246M
| $13.5M | 6.07% | 1,288,450 -56,550 | -4% | -$592K |
|
4
Crinetics Pharmaceuticals
CRNX
$2.92B
| $12.5M | 5.64% | 671,300 -21,700 | -3% | -$405K |
|
|
5
Cytokinetics
CYTK
$4.23B
| $11.9M | 5.36% | 302,500 -104,000 | -26% | -$4.09M |
|
|
6
TELA Bio
TELA
$70.5M
| $11.5M | 5.19% | 1,643,367 +1,166,367 | +245% | +$8.18M |
|
7
Protara Therapeutics
TARA
$120M
| $8.89M | 4% | 2,684,167 +10,136 | +0.4% | +$33.6K |
|
|
TCON
8
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
| $8.25M | 3.72% | 4,125,322 +970,224 | +31% | +$1.94M |
|
9
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $7.89M | 3.56% | 814,250 -298,250 | -27% | -$2.89M |
|
10
Merus
MRUS
$4.98B
| $7.65M | 3.45% | 338,000 | – | – |
|
11
Keros Therapeutics
KROS
$618M
| $7.63M | 3.44% | 276,000 +10,250 | +4% | +$283K |
|
|
INBX
12
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $6.7M | 3.02% | +590,000 | New | +$6.7M |
|
13
Eton Pharmaceutcials
ETON
$464M
| $6.45M | 2.91% | 2,462,500 +83,225 | +3% | +$218K |
|
14
Xoma
XOMA
$392M
| $5.86M | 2.64% | 263,050 -7,950 | -3% | -$177K |
|
|
RETA
15
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $5.58M | 2.52% | 183,750 -223,252 | -55% | -$6.78M |
|
|
CUTR
16
DELISTED
Cutera, Inc.
CUTR
| $5.54M | 2.5% | +147,700 | New | +$5.54M |
|
17
Mersana Therapeutics
MRSN
$36.5M
| $4.84M | 2.18% | 1,047,000 +337,000 | +47% | +$1.56M |
|
18
Vaxcyte
PCVX
$4B
| $4.13M | 1.86% | 190,000 -21,000 | -10% | -$457K |
|
19
Stereotaxis
STXS
$261M
| $3.86M | 1.74% | 2,099,971 -295,629 | -12% | -$544K |
|
20
Edgewise Therapeutics
EWTX
$1.51B
| $3.59M | 1.62% | 451,400 +148,400 | +49% | +$1.18M |
|
21
908 Devices
MASS
$226M
| $3.43M | 1.54% | 166,406 | – | – |
|
|
CMRX
22
DELISTED
Chimerix, Inc.
CMRX
| $2.97M | 1.34% | 1,430,000 -4,473,450 | -76% | -$9.3M |
|
23
Fortress Biotech
FBIO
$76.8M
| $2.73M | 1.23% | 3,247,180 -502,820 | -13% | -$422K |
|
24
Celldex Therapeutics
CLDX
$1.47B
| $2.43M | 1.09% | 90,000 -105,500 | -54% | -$2.84M |
|
25
Liquidia Corp
LQDA
$2.38B
| $2.27M | 1.03% | 521,500 +342,700 | +192% | +$1.49M |
|